丹娜法伯癌症研究院(Dana-Farber Cancer Institute )--甲状腺癌症中心 主任

丹娜法伯癌症研究院(Dana-Farber Cancer Institute )-- 内分泌癌症中心 主任

哈佛医学院助理教授

【专长领域】

头颈肿瘤、内分泌肿瘤、甲状腺癌、唾液腺癌、喉癌

【教育背景】

德国雷根斯堡大学取得医学博士学位

雷根斯堡大学病理科住院医师培训

宾夕法尼亚大学内科实习及住院医师培训

西北大学血液/肿瘤专科培训

【学术著作】(摘选)

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 Oct; 85:29-34.

晚期头颈部鳞状细胞癌免疫检查点抑制剂治疗反应的影像学预测指标

Groden PJ, Lee TC, Bhattacharyya S, Connors J, Lorch J. Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2017; 4:220.

碘难治性转移性乳头状甲状腺癌患者乐伐替尼相关的颈动脉夹层

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 Feb 22; 3(4).

基因移码可预测头颈癌患者抗PD-1/PD-L1反应

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH. Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018 May; 47(5):568-577.

肿瘤PD-L1表达与提高年轻女性口腔鳞状细胞癌患者生存率和降低复发风险相关

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, J?nne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 Apr 1;24(7):1546-1553.

侵袭性碘难治性甲状腺癌对依维莫司的基因相关反应：一项II期试验

【临床试验】(摘选)

Nivolumab Plus Ipilimumab in Thyroid Cancer

纳武单抗联合伊匹单抗免疫疗法治疗甲状腺癌

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

以瑞戈非尼为二线或三线治疗转移性甲状腺髓样癌的研究

A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer

MLN0128在转移性未分化型甲状腺癌的二期研究

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

碘难治性甲状腺癌应用依维莫司

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Bevacizumab/Tarceva和Tarceva/Sulindac在头颈部鳞状细胞癌中的应用